Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
SOUTH SAN FRANCISCO, Calif., and ALBANY, Ga., and WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK), together with The Mended Hearts, Inc. and WomenHeart: The National Coalition for Women with Heart Disease, today announced the launch of ENACT: Empower, Navigate, Activate for Clinical Trials, an initiative designed to champion greater awareness and engagement in cardiovascular clinical trials by reducing barriers, increasing support and empowering patients in groups historically underrepresented in clinical research, including people of color and women to confidently navigate the clinical trial experience from start to finish. ENACT is a joint initiative of The Mended Hearts, Inc. and WomenHeart, made possible through grant funding from Cytokinetics provided to each organization to address their respective constituencies.